Generic substitution of antiepileptic drugs

被引:15
作者
Sander, Josemir W. [2 ,3 ]
Ryvlin, Philippe [4 ]
Stefan, Hermann [5 ,6 ,7 ]
Booth, Daniel R. [8 ]
Bauer, Juergen [1 ]
机构
[1] Univ Bonn, Klin Epileptol, D-53105 Bonn, Germany
[2] UCL Inst Neurol, London, England
[3] Netherlands Fdn, SEIN Epilepsy Inst, Heemstede, Netherlands
[4] Hop Neurol, Lyon, France
[5] Univ Erlangen Nurnberg, Epilepsy Ctr, Erlangen, Germany
[6] Univ Giessen Klinikum, Interdisziplinares Epilepsiezentrum, Marburg, Germany
[7] Marburg GmbH, Marburg, Germany
[8] Bioscript Stirling Ltd, London, England
关键词
AED; antiepileptic drugs; epilepsy; generic drugs; switching; CLINICAL PHARMACOKINETICS; PEDIATRIC-PATIENTS; ECONOMIC-IMPACT; SEIZURE CONTROL; EPILEPSY; CARBAMAZEPINE; COST; BIOEQUIVALENCE; PATIENT; BRAND;
D O I
10.1586/ERN.10.163
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Substitution of antiepileptic drugs with generic formulations may affect individual people, as well as healthcare systems. Analyses of large medical claims databases suggest that generic substitution of antiepileptic drugs is associated with increased morbidity and greater use of healthcare resources. While a single brand-to-generic switch may be associated with a slight increase in overall medical costs, multiple switches may be associated with higher costs, perhaps because different generic agents are not required to be bioequivalent to each other. Generic substitution also affects the individual: along with the possible increased risk of seizures or adverse events, inconsistency of supply may make the medication appear unfamiliar, thus discouraging adherence. Importantly, substitution is often carried out at the dispensing level, without the knowledge or consent of physicians and affected individuals. Therefore, regulatory and professional bodies advocate that substitution should not be carried out without specific counseling of the individual by healthcare professionals on the details and implications of the change.
引用
收藏
页码:1887 / 1898
页数:12
相关论文
共 105 条
  • [1] *AFSSAPS, 2008, SUBST ANT MED
  • [2] Compulsory generic switching of antiepileptic drugs: High switchback rates to branded compounds compared with other drug classes
    Andermann, Frederick
    Duh, Mei Sheng
    Gosselin, Antoine
    Paradis, Pierre Emmanuel
    [J]. EPILEPSIA, 2007, 48 (03) : 464 - 469
  • [3] [Anonymous], 1990, NEUROLOGY, V40, P1641
  • [4] [Anonymous], 2010, LANCET NEUROL, V9, P227, DOI 10.1016/S1474-4422(10)70044-2
  • [5] CLINICAL PHARMACOKINETICS OF ANTIEPILEPTIC DRUGS IN PEDIATRIC-PATIENTS .2. PHENYTOIN, CARBAMAZEPINE, SULTHIAME, LAMOTRIGINE, VIGABATRIN, OXCARBAZEPINE AND FELBAMATE
    BATTINO, D
    ESTIENNE, M
    AVANZINI, G
    [J]. CLINICAL PHARMACOKINETICS, 1995, 29 (05) : 341 - 369
  • [6] CLINICAL PHARMACOKINETICS OF ANTIEPILEPTIC DRUGS IN PEDIATRIC-PATIENTS .1. PHENOBARBITAL, PRIMIDONE, VALPROIC ACID, ETHOSUXIMIDE AND MESUXIMIDE
    BATTINO, D
    ESTIENNE, M
    AVANZINI, G
    [J]. CLINICAL PHARMACOKINETICS, 1995, 29 (04) : 257 - 286
  • [7] Bauer J, 2009, NERVENARZT, V80, P386, DOI 10.1007/s00115-008-2635-7
  • [8] The cost of epilepsy in the United States: An estimate from population-based clinical and survey data
    Begley, CE
    Famulari, M
    Annegers, JF
    Lairson, DR
    Reynolds, TF
    Coan, S
    Dubinsky, S
    Newmark, ME
    Leibson, C
    So, EL
    Rocca, WA
    [J]. EPILEPSIA, 2000, 41 (03) : 342 - 351
  • [9] The economic cost of epilepsy: A review of the literature
    Begley, CE
    Beghi, E
    [J]. EPILEPSIA, 2002, 43 : 3 - 9
  • [10] Generic substitution in the treatment of epilepsy - Case evidence of breakthrough seizures
    Berg, M. J.
    Gross, R. A.
    Tomaszewski, K. J.
    Zingaro, W. M.
    Haskins, L. S.
    [J]. NEUROLOGY, 2008, 71 (07) : 525 - 530